Veracyte (VCYT) appointed Kevin Haas to the new role of chief development and technology officer, effective March 24.
Haas, 40, was previously chief technology officer at Myriad Genetics (MYGN), Veracyte said Monday in a regulatory filing.
Veracyte (VCYT) appointed Kevin Haas to the new role of chief development and technology officer, effective March 24.
Haas, 40, was previously chief technology officer at Myriad Genetics (MYGN), Veracyte said Monday in a regulatory filing.
Comments